T
TaiMed Biologics
Offers Ibalizumab, a monoclonal antibody and a member of HIV viral-entry inhibitor therapy
About TaiMed Biologics
Established in 2007, TaiMed Biologics Inc. operates as a clinical-stage biopharmaceutical company with a strategic focus on the research and development of treatments for infectious diseases, particularly HIV/AIDS. The company's inception traces back to a team of prominent scientists and industry veterans, including Dr. David Ho and Dr. Tse-Wen Chang, who brought extensive experience in virology and immunology. Dr. Ho, a notable Taiwanese-American AIDS researcher, and Dr. Chang, a distinguished immunologist recognized for his work on an anti-IgE antibody that led to the development of Xolair, provided a strong scientific foundation for the company. The establishment of TaiMed was significantly supported by the Taiwanese government's National Development Fund, which was the largest shareholder upon its founding, underscoring a national strategic interest in building a global biotechnology firm.
TaiMed's primary business revolves around developing proprietary monoclonal antibodies (mAbs) to address unmet medical needs. Its flagship product, Trogarzo® (ibalizumab), represents a significant milestone as the first long-acting monoclonal antibody and the first new mechanism of action for HIV treatment in over a decade. Trogarzo® is a humanized monoclonal antibody that functions as a post-attachment HIV-1 inhibitor, binding to the CD4 receptor on host T-cells and blocking the virus from entering. This mechanism is particularly crucial for patients with multi-drug resistant HIV who have limited treatment options remaining. The product is administered intravenously every two weeks, offering a less frequent dosing schedule compared to daily oral antiretrovirals.
The company's business model encompasses both proprietary drug development and Contract Development and Manufacturing Organization (CDMO) services. Revenue is generated through the commercialization of its products, like Trogarzo®, which is marketed in the United States by Theratechnologies. Furthermore, TaiMed leverages its advanced manufacturing facilities and expertise in monoclonal antibodies to offer development and production services to other biopharmaceutical companies, guiding their products from the clinical development stage to market launch. The company's client base includes patients with multi-drug resistant HIV and other biopharmaceutical firms seeking specialized CDMO support. TaiMed operates in the global biopharmaceutical market, with a significant presence in North America and Europe through its partnerships and product approvals.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 49
- Open positions
- None listed
- Dealroom signal
- 75.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Infections and Infectious Diseases, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2010 | $22M | $88M | YFY Biotech Management Company | — |
| SPINOUT✓Other financing | Sep 2007 | $0 | — | Rockefeller University · Columbia University Irving Medical Center | — |
Growth signals
Latest recorded traffic for TaiMed Biologics is 2.7K monthly website visits, down 6.9% over the last three months. TaiMed Biologics's team grew 8.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
TaiMed Biologics in the Taipei ecosystem
The TaiMed Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
YFY Biotech Management Company
Other known investors2 additional known investors
Columbia University Irving Medical Center
Rockefeller University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TaiMed Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TaiMed Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








